NCT07415005 2026-02-17
Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 2 Not yet recruiting
Clinical Trials
13 trialsNCT05740943 2026-01-20
Induction Lorlatinib in Stage III Non-small Cell Lung Cancer
Guangdong Provincial People's Hospital
Phase 2 Active not recruiting
NCT04621188 2025-09-24
Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS)
Intergroupe Francophone de Cancerologie Thoracique
Phase 2 Active not recruiting
NCT07083687 2025-07-24
Lorlatinib in ROS1+ NSCLC With Brain Metastasis
Hunan Cancer Hospital
Phase 2 Not yet recruiting
NCT04111705 2025-04-01
ORAKLE
Intergroupe Francophone de Cancerologie Thoracique
Phase 2 Completed
NCT06682884 2024-11-12
NEOLORA
Peking University People's Hospital
Phase 2 Not yet recruiting
NCT04322890 2024-10-22
PIKACHU
Hunan Province Tumor Hospital
Phase 2 Recruiting
NCT05014464 2024-09-20
ATPase
Hunan Province Tumor Hospital
Phase 2 Recruiting
NCT06378892 2024-04-23
ALK-PPL
Centro di Riferimento Oncologico - Aviano
Phase 2 Recruiting
NCT06092086 2023-10-23
Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC
Guangdong Association of Clinical Trials
Phase 2 Recruiting
NCT03505554 2023-08-07
CRU3
University of Milano Bicocca
Phase 2 Unknown
NCT03439215 2021-07-19
PFROST
Fondazione Ricerca Traslazionale
Phase 2 Unknown
NCT02927340 2021-03-09
A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions
Massachusetts General Hospital
Phase 2 Unknown